Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

Coverage, in order

1. 9d ago
   
   MedCity News indie study

   Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

   Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitive advantage.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.